Cargando…
Effect Modification by Baseline Mortality in the MORDOR Azithromycin Trial
We examined whether baseline mortality risk, as a function of child age and site, modified the azithromycin mortality-reduction effect in the Macrolide Oraux pour Réduire les Décès avec un Oeil sur la Résistance (MORDOR) clinical trial. We used the Cox proportional hazards model with an interaction...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Tropical Medicine and Hygiene
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470539/ https://www.ncbi.nlm.nih.gov/pubmed/30734696 http://dx.doi.org/10.4269/ajtmh.18-1004 |
_version_ | 1783578605310181376 |
---|---|
author | Oron, Assaf P. Burstein, Roy Mercer, Laina D. Arzika, Ahmed M. Kalua, Khumbo Mrango, Zakayo West, Sheila K. Bailey, Robin L. Porco, Travis C. Lietman, Thomas M. |
author_facet | Oron, Assaf P. Burstein, Roy Mercer, Laina D. Arzika, Ahmed M. Kalua, Khumbo Mrango, Zakayo West, Sheila K. Bailey, Robin L. Porco, Travis C. Lietman, Thomas M. |
author_sort | Oron, Assaf P. |
collection | PubMed |
description | We examined whether baseline mortality risk, as a function of child age and site, modified the azithromycin mortality-reduction effect in the Macrolide Oraux pour Réduire les Décès avec un Oeil sur la Résistance (MORDOR) clinical trial. We used the Cox proportional hazards model with an interaction term. Three models were examined representing three sources for the baseline-risk covariate: two using sources external to MORDOR and the third leveraging data within MORDOR. All three models provided moderate evidence for the effect becoming stronger with increasing baseline mortality (P = 0.02, 0.02, and 0.07, respectively) at the rate of approximately 6–12% additional mortality reduction per doubling of baseline mortality. Etiological and programmatic implications of these findings are discussed. |
format | Online Article Text |
id | pubmed-7470539 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The American Society of Tropical Medicine and Hygiene |
record_format | MEDLINE/PubMed |
spelling | pubmed-74705392020-09-04 Effect Modification by Baseline Mortality in the MORDOR Azithromycin Trial Oron, Assaf P. Burstein, Roy Mercer, Laina D. Arzika, Ahmed M. Kalua, Khumbo Mrango, Zakayo West, Sheila K. Bailey, Robin L. Porco, Travis C. Lietman, Thomas M. Am J Trop Med Hyg Articles We examined whether baseline mortality risk, as a function of child age and site, modified the azithromycin mortality-reduction effect in the Macrolide Oraux pour Réduire les Décès avec un Oeil sur la Résistance (MORDOR) clinical trial. We used the Cox proportional hazards model with an interaction term. Three models were examined representing three sources for the baseline-risk covariate: two using sources external to MORDOR and the third leveraging data within MORDOR. All three models provided moderate evidence for the effect becoming stronger with increasing baseline mortality (P = 0.02, 0.02, and 0.07, respectively) at the rate of approximately 6–12% additional mortality reduction per doubling of baseline mortality. Etiological and programmatic implications of these findings are discussed. The American Society of Tropical Medicine and Hygiene 2020-09 2019-02-07 /pmc/articles/PMC7470539/ /pubmed/30734696 http://dx.doi.org/10.4269/ajtmh.18-1004 Text en © The American Society of Tropical Medicine and Hygiene This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Articles Oron, Assaf P. Burstein, Roy Mercer, Laina D. Arzika, Ahmed M. Kalua, Khumbo Mrango, Zakayo West, Sheila K. Bailey, Robin L. Porco, Travis C. Lietman, Thomas M. Effect Modification by Baseline Mortality in the MORDOR Azithromycin Trial |
title | Effect Modification by Baseline Mortality in the MORDOR Azithromycin Trial |
title_full | Effect Modification by Baseline Mortality in the MORDOR Azithromycin Trial |
title_fullStr | Effect Modification by Baseline Mortality in the MORDOR Azithromycin Trial |
title_full_unstemmed | Effect Modification by Baseline Mortality in the MORDOR Azithromycin Trial |
title_short | Effect Modification by Baseline Mortality in the MORDOR Azithromycin Trial |
title_sort | effect modification by baseline mortality in the mordor azithromycin trial |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470539/ https://www.ncbi.nlm.nih.gov/pubmed/30734696 http://dx.doi.org/10.4269/ajtmh.18-1004 |
work_keys_str_mv | AT oronassafp effectmodificationbybaselinemortalityinthemordorazithromycintrial AT bursteinroy effectmodificationbybaselinemortalityinthemordorazithromycintrial AT mercerlainad effectmodificationbybaselinemortalityinthemordorazithromycintrial AT arzikaahmedm effectmodificationbybaselinemortalityinthemordorazithromycintrial AT kaluakhumbo effectmodificationbybaselinemortalityinthemordorazithromycintrial AT mrangozakayo effectmodificationbybaselinemortalityinthemordorazithromycintrial AT westsheilak effectmodificationbybaselinemortalityinthemordorazithromycintrial AT baileyrobinl effectmodificationbybaselinemortalityinthemordorazithromycintrial AT porcotravisc effectmodificationbybaselinemortalityinthemordorazithromycintrial AT lietmanthomasm effectmodificationbybaselinemortalityinthemordorazithromycintrial |